[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580098":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":11,"locations":27,"responsibleParty":41,"collaborators":11,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral tranexamic acid","EXPERIMENTAL",null,[13],"Drug: Oral Tranexamic Acid",{"label":15,"type":16,"description":11,"interventionNames":11},"Control Group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Oral Tranexamic Acid","Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3",[9],[24],{"name":25,"affiliation":5,"role":26},"Joshua Bingham","PRINCIPAL_INVESTIGATOR",[28],{"facility":29,"status":11,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":11},"Mayo Clinic in Arizona","Scottsdale","Arizona","85259","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-111.89903,33.50921,{"lat":39,"lon":38},{"type":26,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Joshua S. Bingham","Associate Professor of Orthopedics, Orthopedic Consultant","100580098","phase-4-postoperative-oral-tranexamic-acid-in-patients-undergoing-primary-total-joint-arthroplasty-100580098",false,"NCT06832878","Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty","Inclusion Criteria\n\n* Adults aged \\> 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol)\n* Written informed consent\n* Patients undergoing primary THA diagnosis of end-stage osteoarthritis\n* Patients receiving spinal anesthesia\n* Patients being discharged on postoperative day 1\n\nExclusion Criteria\n\n* Patients with a TXA allergy\n* Patients undergoing revision procedures\n* Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis\n* Patients receiving general anesthesia\n* Patients being discharged on the same day of surgery\n* Cancer patients\n* Patients with a history of prior VTE event\n* Patients on preoperative anticoagulants other than ASA\n* Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol)\n* Female patients who are on hormonal contraception\n* Patients with history of retinal vein or artery occlusion","ALL","18 Years",{"count":53,"type":54},101,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.",[60],"Arthroplasty","NOT_YET_RECRUITING","2026-01-29",{"date":64,"type":65},"2026-02-02","ACTUAL",{"date":67,"type":54},"2026-06-01",{"date":69,"type":54},"2026-06",{"name":5,"class":6},1]